Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 10-K Report Annual Report
  2. 8-K Event Results of operations
  3. 8-K Event Material agreement · Unregistered share sale · Regulation FD disclosure
  4. 4 Planned sale Director sold 1,666 shares at $18.37 ($30,604)
  5. 8-K Event Regulation FD disclosure
  6. 4 Open-market sale Director sold 2,750 shares at $17.29 ($47,548)
  7. 4 Open-market sale President and CEO sold 9,589 shares at $17.29 ($165,794)
  8. 4 Planned sale Chief Medical Officer sold 4,189 shares at an average $17.46 ($73,130)
  9. 4 Planned sale COFO and Secretary sold 22,844 shares at an average $17.62 ($402,420)
  10. 144 Insider Sale of Securities
  11. 144 Insider Sale of Securities
  12. 144 Insider Sale of Securities
  13. 144 Insider Sale of Securities
  14. 144 Insider Sale of Securities
  15. 144 Insider Sale of Securities
  16. SC 13G/A Stake Amended Statement of Ownership
  17. SC 13G/A Stake Amended Statement of Ownership
  18. SC 13G/A Stake Amended Statement of Ownership
  19. 4 Option exercise COFO and Secretary acquired 50,000 shares (option exercise)
  20. SC 13G Stake Amended Statement of Ownership

Page 11 of 40 · 789 filings